Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Magaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulmann, Caroline Bureau Lenoir, Pascal Godmer, Jean-Jacques Parienti, Xavier Leleu

Blood (2021) 138 (Supplement 1): 83.

https://doi.org/10.1182/blood-2021-148152

Published: 2021

Journal Articles

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1836.

https://doi.org/10.1182/blood-2019-124484

Published: 2019

Journal Articles

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood (2018) 132 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2018-99-111892

Published: 2018

Journal Articles

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

Eileen Mary Boyle, MD MSc, Marie-Odile Petillon, MD, Charles Herbaux, MD, Johanna Mimouni, Xavier Leleu, Lionel Karlin, MD, Chantal Doyen, MD, Marc Wetterwald, MD PhD, Muriel Roussel, MD, Cyrille Hulin, Bruno Royer, MD, Margaret Macro, Philippe Moreau, Karel Fostier, MD, Mamoun Dib, Sabine Brechignac, MD, Caroline Bureau, Gerald Marit, MD, Adrian Tempescul, MD, Marie Lorraine Chretien, Charles Zarnitsky, Cecile Fohrer, MD, Aurore Perrot, MD, Lotfi Benboubker, MD PhD, Laurent Voillat, Jean Valere Malfuson, Clara Mariette, Mourad Tiab, Sophie Rigaudeau, Arnaud Jaccard, MD PhD, Anne-Marie Stoppa, Laure Vincent, Jean Claude Eisenmann, MD, Laurent Frenzel, Bertrand Arnulf, MD, Mohamad Mohty, MD PhD, Philippe Rodon, MD, Brigitte Kolb, Olivier Decaux, MD PhD, Pascal Godmer, David Beauvais, Benjamin Carpentier, Sarah Bonnet, MD, Thomas Longval, Mathieu Dewevre, Herve Avet-Loiseau, MD PhD, Michel Attal, Susanna Schraen, PharmD, Thierry Facon

Blood (2016) 128 (22): 2138.

https://doi.org/10.1182/blood.V128.22.2138.2138

Published: 2016

Journal Articles

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Gabriel Etienne, MD, PHD, Stephanie Dulucq, MD, Axelle Lascaux, MD, Anna Schmitt, MD, Audrey Bidet, Marie-Pierre Fort, Eric Lippert, Caroline Bureau, Didier Adiko, MD, Sandrine Hayette, Josy Reiffers, MD, Franck E. Nicolini, MD PhD, Francois-Xavier Mahon, MD, PhD

Blood (2013) 122 (21): 4029.

https://doi.org/10.1182/blood.V122.21.4029.4029

Published: 2013

Journal Articles

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Gabriel Etienne, MD, PHD, Nicolini E Nicolini, MD, PhD, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, MD, PhD, Isabelle Tigaud, MD, Stephane Morisset, Stat., Caroline Bureau, Didier Adiko, Gerald Marit, MD, Josy Reiffers, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 3754.

https://doi.org/10.1182/blood.V120.21.3754.3754

Published: 2012

NARROW

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Email alerts

ASH Publications

American Society of Hematology

Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only